Dihexa reconstitution calculator
angiotensin IV analog · nootropic
Dihexa is a small peptide-derivative developed at Washington State University from angiotensin IV research, aimed at synapse formation - with a famous in-vitro claim of being orders of magnitude more potent than BDNF at synaptogenesis. Human evidence: none published. It's also the rare 'peptide' usually taken orally, which changes all the math.
Enter vial size, water volume, and the dose your provider gave you.
This tool converts the numbers you enter (dose ÷ concentration = volume). It never suggests a dose. The FDA has documented hospitalizations caused by mg / ml / unit conversion errors with vial-and-syringe products - if the readout surprises you, stop and verify with your prescriber or pharmacist.
Questions people actually search
Is Dihexa really 'ten million times more potent than BDNF'?
That figure comes from an in-vitro synaptogenesis assay - a cell-culture comparison, not a human effect size. No published human trial of Dihexa exists, so no human potency claim is measurable, let alone that one.
Is Dihexa taken orally or injected?
Its designers built it for oral blood-brain-barrier penetration, and the gray market mostly sells capsules or oil solutions; vials exist but are the minority. For solutions, the same concentration math applies: amount ÷ concentration = volume.
What are Dihexa's risks?
Unknown in humans - nothing is published. Mechanistically, a compound built to promote synapse growth through the HGF/c-Met pathway raises oncological questions (c-Met is an oncogene), which is exactly the kind of concern only trials can resolve.